tetano
Editor, Senior Moderator
Nat Commun
. 2020 Aug 27;11(1):4303.
doi: 10.1038/s41467-020-18159-4.
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Tal Noy-Porat[SUP] 1 [/SUP], Efi Makdasi[SUP] 1 [/SUP], Ron Alcalay[SUP] 1 [/SUP], Adva Mechaly[SUP] 1 [/SUP], Yinon Levy[SUP] 1 [/SUP], Adi Bercovich-Kinori[SUP] 1 [/SUP], Ayelet Zauberman[SUP] 1 [/SUP], Hadas Tamir[SUP] 1 [/SUP], Yfat Yahalom-Ronen[SUP] 1 [/SUP], Ma'ayan Israeli[SUP] 1 [/SUP], Eyal Epstein[SUP] 1 [/SUP], Hagit Achdout[SUP] 1 [/SUP], Sharon Melamed[SUP] 1 [/SUP], Theodor Chitlaru[SUP] 1 [/SUP], Shay Weiss[SUP] 1 [/SUP], Eldar Peretz[SUP] 1 [/SUP], Osnat Rosen[SUP] 1 [/SUP], Nir Paran[SUP] 1 [/SUP], Shmuel Yitzhaki[SUP] 1 [/SUP], Shmuel C Shapira[SUP] 1 [/SUP], Tomer Israely[SUP] 1 [/SUP], Ohad Mazor[SUP] 2 [/SUP], Ronit Rosenfeld[SUP] 3 [/SUP]
Affiliations
Abstract
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD. A subset of the antibodies exert their inhibitory activity by abrogating binding of the RBD to the human ACE2 receptor. The human monoclonal antibodies described here represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection.
. 2020 Aug 27;11(1):4303.
doi: 10.1038/s41467-020-18159-4.
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Tal Noy-Porat[SUP] 1 [/SUP], Efi Makdasi[SUP] 1 [/SUP], Ron Alcalay[SUP] 1 [/SUP], Adva Mechaly[SUP] 1 [/SUP], Yinon Levy[SUP] 1 [/SUP], Adi Bercovich-Kinori[SUP] 1 [/SUP], Ayelet Zauberman[SUP] 1 [/SUP], Hadas Tamir[SUP] 1 [/SUP], Yfat Yahalom-Ronen[SUP] 1 [/SUP], Ma'ayan Israeli[SUP] 1 [/SUP], Eyal Epstein[SUP] 1 [/SUP], Hagit Achdout[SUP] 1 [/SUP], Sharon Melamed[SUP] 1 [/SUP], Theodor Chitlaru[SUP] 1 [/SUP], Shay Weiss[SUP] 1 [/SUP], Eldar Peretz[SUP] 1 [/SUP], Osnat Rosen[SUP] 1 [/SUP], Nir Paran[SUP] 1 [/SUP], Shmuel Yitzhaki[SUP] 1 [/SUP], Shmuel C Shapira[SUP] 1 [/SUP], Tomer Israely[SUP] 1 [/SUP], Ohad Mazor[SUP] 2 [/SUP], Ronit Rosenfeld[SUP] 3 [/SUP]
Affiliations
- PMID: 32855401
- DOI: 10.1038/s41467-020-18159-4
Abstract
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD. A subset of the antibodies exert their inhibitory activity by abrogating binding of the RBD to the human ACE2 receptor. The human monoclonal antibodies described here represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection.